Literature DB >> 25065740

The histone demethylase PHF8 is an oncogenic protein in human non-small cell lung cancer.

Yuzhou Shen1, Xufeng Pan1, Heng Zhao2.   

Abstract

PHF8 is a JmjC domain-containing protein and erases repressive histone marks including H4K20me1 and H3K9me1/2. It binds to H3K4me3, an active histone mark usually located at transcription start sites (TSSs), through its plant homeo-domain, and is thus recruited and enriched in gene promoters. PHF8 is involved in the development of several types of cancer, including leukemia, prostate cancer, and esophageal squamous cell carcinoma. Herein we report that PHF8 is an oncogenic protein in human non-small cell lung cancer (NSCLC). PHF8 is up-regulated in human NSCLC tissues, and high PHF8 expression predicts poor survival. Our in vitro and in vivo evidence demonstrate that PHF8 regulates lung cancer cell proliferation and cellular transformation. We found that PHF8 knockdown induces DNA damage and apoptosis in lung cancer cells. PHF8 promotes miR-21 expression in human lung cancer, and miR-21 knockdown blocks the effects of PHF8 on proliferation and apoptosis of lung cancer cells. In summary, PHF8 promotes lung cancer cell growth and survival by regulating miR-21.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Apoptosis; Non-small cell lung cancer; PHF8; miR-21

Mesh:

Substances:

Year:  2014        PMID: 25065740     DOI: 10.1016/j.bbrc.2014.07.076

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  22 in total

Review 1.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

Review 2.  Inhibitors of Protein Methyltransferases and Demethylases.

Authors:  H Ümit Kaniskan; Michael L Martini; Jian Jin
Journal:  Chem Rev       Date:  2017-03-24       Impact factor: 60.622

Review 3.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

4.  MicroRNAs in Genetic Etiology of Human Diseases.

Authors:  Melis Olcum; Kemal Ugur Tufekci; Sermin Genc
Journal:  Methods Mol Biol       Date:  2022

5.  Stabilization of histone demethylase PHF8 by USP7 promotes breast carcinogenesis.

Authors:  Qian Wang; Shuai Ma; Nan Song; Xin Li; Ling Liu; Shangda Yang; Xiang Ding; Lin Shan; Xing Zhou; Dongxue Su; Yue Wang; Qi Zhang; Xinhua Liu; Na Yu; Kai Zhang; Yongfeng Shang; Zhi Yao; Lei Shi
Journal:  J Clin Invest       Date:  2016-05-16       Impact factor: 14.808

6.  MiR-101 reverses the hypomethylation of the LMO3 promoter in glioma cells.

Authors:  Xiaoping Liu; Qianqian Lei; Zhibin Yu; Gang Xu; Hailin Tang; Wei Wang; Zeyou Wang; Guiyuan Li; Minghua Wu
Journal:  Oncotarget       Date:  2015-04-10

7.  The Histone Demethylase PHF8 Is Essential for Endothelial Cell Migration.

Authors:  Lunda Gu; Juliane Hitzel; Franziska Moll; Christoph Kruse; Randa Abdel Malik; Jens Preussner; Mario Looso; Matthias S Leisegang; Dieter Steinhilber; Ralf P Brandes; Christian Fork
Journal:  PLoS One       Date:  2016-01-11       Impact factor: 3.240

8.  miR-203 facilitates tumor growth and metastasis by targeting fibroblast growth factor 2 in breast cancer.

Authors:  Shuqian He; Guihui Zhang; He Dong; Maoqiang Ma; Qing Sun
Journal:  Onco Targets Ther       Date:  2016-10-11       Impact factor: 4.147

9.  Histone demethylase PHF8 promotes cell growth and metastasis of non-small-cell lung cancer through activating Wnt/β-catenin signaling pathway.

Authors:  Yan Hu; Hanshuo Mu; Ying Yang
Journal:  Histol Histopathol       Date:  2021-06-08       Impact factor: 2.303

10.  The histone demethylase PHF8 promotes prostate cancer cell growth by activating the oncomiR miR-125b.

Authors:  Qiang Ma; Zhuo Chen; Guojin Jia; Xueqiang Lu; Xuefeng Xie; Wei Jin
Journal:  Onco Targets Ther       Date:  2015-08-10       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.